medigraphic.com

2019, Number 4

Next >>

Rev Clin Esc Med 2019; 9 (4)

Implante valvular aórtico transcatéter

Vega CJC, Mora AM, Vásquez JS, Arias DF

Language: Spanish
References: 18
Page: 7-15
PDF size: 289.22 Kb.


ABSTRACT

Transcatheter aortic valve implantation (TAVI) is a revolutionary, newflanged and, mostly, effective technique, which is used in patients with severe aortic stenosis who have contraindications for valve replacement surgery. Thanks to advances over the years, this technique has been successfully implemented and has proven to be superior to medical management, which is why it has become the main therapeutic option for such patients. Additionally, it is expected that in the near future it will be the choice of treatment for patients with moderate aortic stenosis too.


REFERENCES

  1. Otto C, Bonow R. Cap 63. Valvular Heart Disease. Braunwalds Heart Disease. 10th edition. 2015.

  2. Moris C, Pascual I, Avanzas P. ¿Será el TAVI el tratamiento de elección para la estenosis aóritca? Rev Esp Cardiol. 2016; 69(12): 1131–1134.

  3. Leon M. Transcatheter aortic valve replacement: A breakthrough medical therapy! The 20-year odyssey, and now, a 10-year anniversary. Archives of Cardiovascular Disease. 2012; 105: 129—131.

  4. Cribier A. Development of transcatheter aortic valve implantation (TAVI): A 20-year odyssey. Archives of Cardiovascular Disease. 2012; 105: 146—152.

  5. Vahanian A, Alfieri O, Andreotti F, Antunes M, Barón-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012). European Heart Journal. 2012; 33: 2451–2496.

  6. Ogara P, Loscalzo J. Cardiopatías vavulares. Capítulo 237. Harrison Principios de Medicina Interna. Volumen 2, edición 18. 2002; McGraw Hill.

  7. Cerrato E, Nombela-Franco L, Nazif T, Eltchaninoff H, Søndergaard L, Ribeiro H, et al. Evaluation of current practices in transcatheter aortic valve implantation: The WRITTEN (WoRldwIde TAVI ExperieNce) survey. International Journal of Cardiology. 2016; 228: 640–647.

  8. Leon M, Smith C, Mack M, Miller C, Moses J. Svensson L, et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. N Engl J Med. 2010; 363: 1597-1607.

  9. Phan K, Wongb S, Phan S, Ha H, Qian P, Yan T. Transcatheter Aortic Valve Implantation (TAVI) in Patients With Bicuspid Aortic Valve Stenosis – Systematic Review and Meta-Analysis. Heart, Lung and Circulation. 2015; 24: 649–659.

  10. Melidi E, Latsios G, Toutouzas K, Vavouranakis M, Tolios I, Gouliami M, et al. Cardio-anesthesiology considerations for the trans-catheter aortic valve implantation (TAVI) procedure. Hellenic Journal of Cardiology. 2016; 10: 1-6.

  11. Czerwińska-Jelonkiewicz K, Zembala, Dąbrowski, Witkowski A, Ochała A, Kochman J, et al. Can TAVI patients receive aspirin monotherapy as patients after surgical aortic bioprosthesis implantation? Data from the Polish Registry — POL-TAVI. Int J Cardiol 2016; http://dx.doi.org/10.1016/j.ijcard. 2016.11.095.

  12. Avanzas P, Pascual I, del Valle R, Morís C. Indicaciones del TAVI. ¿En qué se basan?. Rev Esp Cardiol Supl. 2015; 15:27-35.

  13. Collas V, Chong Y, Rodrigus I, Vandewoude M, Bosmans J. Predictive mortality estimation in older patients undergoing TAVI comparison of the logistic EuroSCORE, EuroSCORE II and STS-score. European Geriatric Medicine. 2015; 6: 11–14.

  14. Sabatéa M, Cánovasb S, García E, Hernández Antolínc R, Marotoc L, Hernández J, et al. Predictores de mortalidad hospitalaria y a medio plazo tras el reemplazo valvular aórtico transcatéter: datos del registro nacional TAVI 2010-2011. Cir Cardiov. 2013; 20(4): 174–183.

  15. Avinée G, Durand E, Elhatimi S, Bauer F, Glinel B, Dacher JN, et al. Trends over the past 4 years in population characteristics, 30-day outcomes and 1-year survival in patients treated with transcatheter aortic valve implantation. Archives of Cardiovascular Disease. 2016; 109: 457—464.

  16. Fauchère I, Weber D, Maier W, Altwegg L, Lüscher T, Grünenfelder J, et al. Rehabilitation after TAVI compared to surgical aortic valve replacement. I Jour Card. 2014; 3: 564-566.

  17. Jones B, Krishnaswamy A, Kapadia S. ¿La protección embólica debe pasar a ser una medida estándar para la prevención del ictus durante el TAVI? Rev Esp Cardiol. 2016; 69(10): 890–893.

  18. Abdul-Jawad O, Puria R, Rode´s-Cabau J. Dispositivos de protección embólica durante el TAVI: evidencias e incertidumbres actuales. Rev Esp Cardiol. 2016; 69(10): 962–972.




2020     |     www.medigraphic.com